SCHEMBL5366144

SCHEMBL5366144

CC(C)(C)OC(=O)N1CCCC(Oc2ccccc2Br)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.50
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48
USP30 Q70CQ3 3/20 0.47
CHEK2 O96017 1/20 0.45
GPR119 Q8TDV5 1/20 0.44
HPGDS O60760 1/20 0.43
APLNR P35414 1/20 0.43
KDM1A O60341 1/20 0.43
UCHL1 P09936 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14559939 1.00 PDE4B (0.50) PDE4BPRMT5WDR77USP30CHEK2
SCHEMBL5414961 1.00 PDE4B (0.50) PDE4BPRMT5WDR77USP30CHEK2
SCHEMBL7090955 0.95 PDE4B (0.46) PDE4BPRMT5WDR77USP30CHEK2
SCHEMBL1927899 0.93 USP30 (0.52) PDE4BPRMT5WDR77USP30GPR119
SCHEMBL3954269 0.88 USP30 (0.47) PDE4BPRMT5WDR77USP30GPR119
SCHEMBL5371739 0.87 PDE4B (0.52) PDE4BPRMT5WDR77USP30CHEK2
SCHEMBL69206 0.85 KDM1A (0.56) PDE4BGPR119KDM1A
SCHEMBL15058781 0.85 PRMT5 (0.50) PDE4BPRMT5WDR77USP30CHEK2
SCHEMBL15058778 0.85 PRMT5 (0.50) PDE4BPRMT5WDR77USP30CHEK2
SCHEMBL23582027 0.84 DGAT2 (0.57) PDE4BPRMT5WDR77USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186715-B2 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-03-06 US disclosed
EP-1370558-B1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-24 EP disclosed
US-20040082590-A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY 2004-04-29 US disclosed
EP-1370558-A1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-17 EP disclosed
WO-2002059117-A1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082590-A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists MC1R, MC4R, MC5R PDE4B 734/4885PRMT5 593/4885WDR77 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.